GlaxoSmithKline's Nucala beats AZ's Fasenra to the IL-5 punch in nasal polyps

GlaxoSmithKline’s antibody drug Nucala may not have been the first biologic approved in nasal polyps—that distinction goes to Sanofi and Regeneron’s Dupixent. But on Thursday, it did become the first IL-5 inhibitor to break into the indication, notching a win over AstraZeneca’s would-be rival Fasenra.